Arrowhead Pharma 2025财年第一季度GAAP每股收益$(1.39)，不及预期$(0.63)，销售收入$2.50M，不及预期$65.47M

财报速递2025-02-11
Arrowhead Pharma（纳斯达克代码：ARWR）公布季度每股亏损$(1.39)，比分析师一致预期的$(0.63)低120.63%。与去年同期每股亏损$(1.24)相比下降12.1%。公司报告季度销售收入为$2.50百万，比分析师一致预期的$65.47百万低96.18%。与去年同期$3.55百万的销售收入相比下降29.60%。

以上内容来自Benzinga Earnings专栏，原文如下：

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.63) by 120.63 percent. This is a 12.1 percent decrease over losses of $(1.24) per share from the same period last year. The company reported quarterly sales of $2.50 million which missed the analyst consensus estimate of $65.47 million by 96.18 percent. This is a 29.60 percent decrease over sales of $3.55 million the same period last year.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法